Zim Laboratories Limited — Investor Meet, 14-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Zim Laboratories reported Q1 FY26 operating income at INR 71.8 Cr (down 12.3% YoY) with a net loss of INR 1.9 Cr. This was primarily due to softer Middle East orders and an EU-GMP inspection. The inspection observations focused on documentation and manual systems, not product quality. Management is submitting a corrective action plan by August 31, anticipating re-inspection in 6-9 months. While EU product launches may shift, UK operations and global partnerships are unaffected. The base business and other markets continue to perform, and management expresses confidence in its long-term strategy.